Initial dose: mg subcutaneously once a day for 1 week; this dose is intended to reduce gastrointestinal symptoms and is not an effective dose for glycemic control.
Maintenance dose: Inject mg subcutaneously once a day; if acceptable glycemic control is not achieved, may increase to mg subcutaneously once a day
Maximum dose: mg once a day
-Consider dose reduction of the insulin secretagogue to reduce the risk of hypoglycemia.
-This drug is not recommended as a first-line therapy for patients with inadequate glycemic control on diet and exercise.